A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer

NCT07679360 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

1000

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Trastuzumab Rezetecan for Injection
DRUG: Adebrelimab Injection
DRUG: Capecitabine tablets
DRUG: Pembrolizumab injection

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.